Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

36

Revenue 2017

Xtandi

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Xtandi was produced by Astellas.

J&J puts pressure on rivals with new Erleada okay in prostate cancer

J&J puts pressure on rivals with new Erleada okay in prostate cancer

FDA previously granted priority review in this indication. Johnson &Johnson has bagged an FDA approval for Erleada in metastatic castration-sensitive prostate cancer (mCSPC), gaining an advantage over main rival Xtandi ... Androgen inhibitor Erleada

Trial backs role for Lynparza in second-line prostate cancer

Trial backs role for Lynparza in second-line prostate cancer In the 340-patient trial,   Lynparza was compared to hormonal treatment with Pfizer’s Xtandi (enzalutamide) or Johnson &Johnson’s Zytiga (abiraterone acetate) in this second-line setting, focusing on patients ... previously treated with Zytiga,

Bayer bags FDA nod for early prostate cancer drug darolutamide

Bayer bags FDA nod for early prostate cancer drug darolutamide now subject to generic competition – as well as Pfizer/Astellas’ Xtandi (enzalutamide). ... Zytiga is only approved for metastatic CRPC and, as Xtandi and Erleada were only approved for non-metastatic CRPC in the last few months, Nubeqa has an

Pfizer adds Array to cancer arsenal with $11bn acquisition

Pfizer adds Array to cancer arsenal with $11bn acquisition cancers, where it has the blockbusters Ibrance and the Astellas co-marketed prostate cancer treatment Xtandi. ... The 2016 Medivation buyout saw its value drop when Xtandi failed to live up to expectations, and a late stage PARP inhibitor failed in phase

Bayer gains FDA priority review for prostate cancer drug

Bayer gains FDA priority review for prostate cancer drug Once approved, the drug will go up against Johnson &Johnson’s Zytiga (with the first generics now reaching the market), its follow-up Erleada, and Pfizer/Astellas' Xtandi. ... Darolutamide won’t have an easy time competing in against these products,

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics